Tag: trial
Effectiveness of Fludrocortisone and Hydrocortisone vs. Hydrocortisone Alone in Septic Shock
Steroid use in sepsis is controversial. For example, fludrocortisone–hydrocortisone together may improve survival in septic shock, while hydrocortisone alone may not. A recent subgroup analysis of the APROCCHSS trial... read more
The Easiest Way to Reduce Antibiotic Resistance Might be Shorter Duration
Antibiotic stewardship garners a lot of attention these days, but we face unique challenges to execute guidelines successfully given that we write more than 13 million antibiotic prescriptions every year in EDs. Variations... read more
PEEP May Cause Harm in Less Severe ARDS
A higher positive end-expiratory pressure (PEEP) strategy may cause harm in adult patients with acute respiratory distress syndrome (ARDS) whose subphenotype is characterized by less inflammation and lower severity of illness. The... read more
Ketones Alleviates COVID-19-related ARDS
In this randomized controlled trial, supplementation with beta-hydroxybutyrate improved inflammatory biomarkers and reduced the length of hospitalization in adults with COVID-19–related acute respiratory distress syndrome... read more
BARDA Selected Host-directed Therapeutic Candidates to Address ARDS
Biomedical Advanced Research and Development Authority (BARDA) has selected host-directed therapeutic candidates for inclusion in a phase 2 platform clinical trial to address acute respiratory distress syndrome (ARDS). Currently,... read more
Haloperidol vs. Placebo in ICU Patients with Delirium
We assessed long-term outcomes in acutely admitted adult patients with delirium treated in intensive care unit (ICU) with haloperidol versus placebo. In acutely admitted adult ICU patients with delirium, haloperidol treatment... read more
Ilofotase Alfa Doesn’t Improved Survival Among Critically Ill Patients with SA-AKI
Sepsis-associated acute kidney injury (SA-AKI) in patients admitted to an intensive care unit is associated with significant morbidity and mortality. There is currently no pharmaceutical treatment. Although we found no... read more
Intravenous Vitamin C for COVID-19 Patients
In hospitalized patients with COVID-19, vitamin C had low probability of improving the primary composite outcome of organ support–free days and hospital survival. Enrollment was terminated after statistical triggers... read more
Inflammatory Subphenotypes in Patients at Risk of ARDS
We identified hyper- and non-hyperinflammatory subphenotypes in patients at risk of ARDS upon presentation to the emergency department. These subphenotypes remained identifiable over time and a hyperinflammatory subphenotype... read more
Convalescent Plasma Cuts Death by 10% in COVID Patients on Mechanical Ventilation
A randomized clinical trial in Belgium finds that convalescent plasma reduces death rates by about 10% in COVID-19 patients requiring invasive mechanical ventilation. University of Liege researchers led the open-label... read more
Haloperidol Efficacy to Decrease Delirium Burden in Critically Ill Patients
This trial, that was stopped early, did not show evidence that haloperidol reduces delirium and coma in critically ill patients with delirium. The beneficial effects on some agitation-related outcomes and lower sedative... read more
Optimal RRT for Critically Ill Patients with Severe AKI
In critically ill patients with severe acute kidney injury (AKI), initiation of continuous renal replacement therapy (CRRT), as compared to intermittent hemodialysis (IHD), was associated with a significant reduction in the... read more
Haloperidol and Delirium: What is Next?
Haloperidol is, by far, the best-studied antipsychotic in ICU, appears to be safe in the dosing range used in these two trials and is easy to administer and titrate. For these reasons, if a clinician chooses to pharmacologically... read more
Delirium in Critically Ill Patients – Haloperidol Treatment
Haloperidol may reduce mortality and likely result in little to no change in the occurrence of SAEs/SARs compared with placebo in critically ill patients with delirium. However, the results were not statistically significant... read more
AKI Defined by Fluid-Corrected Creatinine in Premature Neonates
In this secondary analysis of the multicenter PENUT trial, we describe fluid-corrected acute kidney injury (AKI) and evaluate associations with short-term and long-term outcomes in premature neonates with fluid-corrected... read more
Ciprofol Sedation Efficacy and Safety in Mechanical Ventilated ICU Patients
Ciprofol was well tolerated, with a noninferior sedation profile to propofol in Chinese ICU patients undergoing MV for a period of 6–24 hours. Of the 135 patients enrolled, 129 completed the study. The primary endpoint-sedation... read more
Duration of Device-Based Fever Prevention After Cardiac Arrest
While fever prevention for 72 hours after cardiac arrest has been endorsed by international guidelines since 2005, there is a lack of randomized control trial (RCT) generated data supporting this after the initial 24 hours... read more
Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19
Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment effect (HTE) across individuals. Better understanding... read more
Are Two Shocks Better Than One?
Overall, the trial conducted by Cheskes et al contributes meaningfully to our understanding of the use of alternative defibrillation strategies for refractory ventricular fibrillation before widespread incorporation of double... read more
Hydrocortisone in Severe Community-Acquired Pneumonia
Among patients with severe community-acquired pneumonia being treated in the ICU, those who received hydrocortisone had a lower risk of death by day 28 than those who received placebo. A total of 800 patients had undergone... read more
No Benefits For Using 4-Factor Prothrombin Complex Concentrate (4F-PCC) in Trauma Patients
Early administration of 4-factor prothrombin complex concentrate (4F-PCC) was of no benefit to patients with trauma at risk of massive transfusion, the randomized PROCOAG trial from France showed. Among over 300 patients... read more
Oral PCSK9 Inhibitor Could Help Reduce LDL-C by 60%
New research from a phase 2b trial presented at American College of Cardiology meeting (ACC) 2023 suggests an oral PCSK9 inhibitor could help reduce LDL-C by 60% in patients with or at-risk for atherosclerotic cardiovascular... read more
